We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.45 | 3.40 | 3.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.32 | 3.11M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/9/2020 08:32 | https://twitter.com/ | bloomberg2 | |
28/9/2020 08:28 | Our mkt cap is 35m..very different !! We have other opps as well | nico115 | |
28/9/2020 08:25 | I know, i know....feel gutted | stumbleupon | |
28/9/2020 08:20 | Dr Suzy Dilly, Chief Executive Officer commented: "I am delighted to be able to share these exciting results today, which are an accumulation of a lot of work by the wider team, both within and external to ValiRx. While considering these results it is important to remember that this is only the first clinical trial using VAL201, so this data has been generated using the utmost caution in sequentially dosing patients. Nevertheless, the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug. With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate." Professor Alan Boyd, Consultant Pharmaceutical Physician and Medical Monitor for the study commented: "Development of effective treatments with low-side effects for patients with prostate cancer who have relapsed after radiotherapy is essential and will improve the lives of patients during treatment. I am pleased to have contributed to a project that has demonstrated such a good safety and tolerability profile while giving the first indications of a favourable effect on the patient's disease." | hope67 | |
28/9/2020 08:18 | Does anyone here remember British Biotech and its cancer drug marimastat?A sobering reminder of what can happen in phase three clinical trials. | steeplejack | |
28/9/2020 08:16 | This is the real rise now the profit takers from last week are out... mad but hay ho. Once the media get hold of these results £1 easy. | 412069 | |
28/9/2020 08:16 | Am surprised we are not over 100p already on this huge news.54% is great result compared to most cancer drugs at such test stage | jungmana | |
28/9/2020 08:15 | might just have had large holders selling into the news first thing, now the mm's make some money... | jusjusjus | |
28/9/2020 08:15 | Just got in better late than never | bobaxe1 | |
28/9/2020 08:15 | One extremely happy holder here. Offers will come on from big pharmas for val201 soon.Amazingly cheap at GBP 36m market cap right now | jungmana | |
28/9/2020 08:14 | People franticly buying back when they sold above 65 | justtrying1 | |
28/9/2020 08:14 | Nt to sell at the rise,now nt to buy at the drop | arab3 | |
28/9/2020 08:13 | The Company intends to share these results with potential industry partners to evaluate all options for further clinical development of VAL201. don't let yours go cheap | hope67 | |
28/9/2020 08:09 | Hmmmm. Works half the time, not dangerous, we hope to talk to some of the big players, proper results by end of year. Maybe that’s good news in this industry, I hope so. | guss | |
28/9/2020 08:09 | I think all the upside for VAL has happened in short term Now the story is PYC who are TRIPLE WHAMMY winners PYC haven't RNSed this yet | the stigologist | |
28/9/2020 08:08 | Great results guys, obviously you will getting some sells now, but should be going higher later. All the best! | jassyb55 | |
28/9/2020 08:08 | Just the start! | wulber | |
28/9/2020 08:06 | lotsa numpties taking their 10%...this has much further to rise | fez | |
28/9/2020 08:02 | Managed to bag another 30k at 64.75p on open and expecting £1 today | tburns | |
28/9/2020 08:01 | Well I got that wrong !!I thought 80p okie lol | nico115 | |
28/9/2020 07:56 | Yeah, you're right mally. - I'm gonna sell the lot in five minutes, and put the lot into BT. - or the 3:45 at Newton Abbot. | 801710245 | |
28/9/2020 07:56 | NOTE Physiomics earlier this year signed a deal with the No.1 Prostate Cancer drug seller Astellas (Xtandi (enzalutamide) which sells $3bn p.a.) Could they be a bridge for VAL to approach Astellas with regard to partnering VAL201 with Xtandi ? | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions